Success Metrics

Clinical Success Rate
100.0%

Based on 15 completed trials

Completion Rate
100%(15/15)
Active Trials
6(26%)
Results Posted
53%(8 trials)

Phase Distribution

Ph phase_4
5
22%
Ph not_applicable
1
4%
Ph phase_1
7
30%
Ph phase_3
5
22%
Ph phase_2
3
13%

Phase Distribution

7

Early Stage

3

Mid Stage

10

Late Stage

Phase Distribution21 total trials
Phase 1Safety & dosage
7(33.3%)
Phase 2Efficacy & side effects
3(14.3%)
Phase 3Large-scale testing
5(23.8%)
Phase 4Post-market surveillance
5(23.8%)
N/ANon-phased studies
1(4.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

15 of 15 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

6

trials recruiting

Total Trials

23

all time

Status Distribution
Active(8)
Completed(15)

Detailed Status

Completed15
Recruiting6
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
23
Active
6
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 17 (33.3%)
Phase 23 (14.3%)
Phase 35 (23.8%)
Phase 45 (23.8%)
N/A1 (4.8%)

Trials by Status

completed1565%
not_yet_recruiting29%
recruiting626%

Recent Activity

Clinical Trials (23)

Showing 20 of 23 trialsScroll for more
NCT07384429Phase 4

Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease

Recruiting
NCT07480096Phase 2

Efficacy and Safety of Lemborexant for Patients With Cirrhosis and Sleep Problems

Completed
NCT05463861Phase 4

Lemborexant in Delayed Sleep Phase Syndrome

Completed
NCT07407400Phase 4

Lemborexant for Sleep and Delirium Prevention in Elderly ICU Patients

Not Yet Recruiting
NCT05344443Phase 4

Lemborexant Shift Work Treatment Study

Completed
NCT05594589Phase 2

A Study to Assess the Pharmacodynamics of Lemborexant in Korean Participants With Insomnia Disorder

Completed
NCT06874855Phase 4

Lemborexant in Delayed Sleep Phase Syndrome

Recruiting
NCT06779149Not Applicable

Efficacy of CBT-I and Lemborexant Medication for Different Subtypes of Chronic Insomnia

Recruiting
NCT06843187Phase 2

Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)

Not Yet Recruiting
NCT06262594Phase 3

Lemborexant Treatment of Insomnia Linked to Epilepsy

Recruiting
NCT05618002

Lemborexant vs Zopiclone vs Clonidine for Insomnia Treatment in Chronic Pain Patients

Recruiting
NCT04549168Phase 3

A Study of Lemborexant in Chinese Participants With Insomnia Disorder

Completed
NCT04818086Phase 1

Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder

Completed
NCT02783729Phase 3

Study of the Efficacy and Safety of Lemborexant in Subjects 55 Years and Older With Insomnia Disorder (SUNRISE 1)

Completed
NCT06496282Phase 3

Lemborexant on Improving Sleep Quality Among Hospital Rotating Shift Workers

Recruiting
NCT04573556

A Study to Evaluate the Safety of DAYVIGO (Lemborexant) Tablets in Participants With Insomnia.

Completed
NCT04890561Phase 1

A Study to Evaluate Lemborexant in Milk of Healthy Lactating Women

Completed
NCT04555733Phase 1

A Single and Multiple Dose Study of Lemborexant in Healthy Chinese Participants

Completed
NCT03440424Phase 1

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects

Completed
NCT03443063Phase 1

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment

Completed

Drug Details

Intervention Type
DRUG
Total Trials
23